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ABSTRACT
Over the last decade, European countries faced several emerging and re-emerging animal diseases as 
well as zoonotic diseases. During these episodes, the laboratory diagnostic capabilities were a key 
factor to rapidly control and/or eradicate them. Because of the associated socio-economic and health 
consequences, it is crucial to react rapidly and efficiently, not only during crisis but also in peacetime 
(i.e. preparedness). However, to date, there is no published method to identify diseases with 
diagnostic gaps and to prioritise assays to be implemented. This study was conducted based on the 
outcome of a prioritisation exercise in which 29 epizootic and exotic diseases with high risk of 
emergence or re-emergence in Belgium (Bianchini et al., 2020) were listed. Knowledge mapping was 
used to visualise and identify gaps in the diagnostic procedures for different epidemiological 
scenarios at national level. To fill these gaps, an overview of diagnostic capabilities at national and 
international level (laboratories and kits providers or manufacturers) as well as the published assays in 
the scientific literature and the prescribed assays by international institutions and kits providers was 
carried out. The outcome of this study revealed the usefulness of knowledge mapping as a tool to 
identify gaps and ultimately gain insight on alternatives for better preparedness and responsiveness 
While this exercise was limited to Belgium, we believe this exercise can benefit other countries and 
thereby enhancing knowledge sharing and collaboration to increase diagnostic capabilities for a 
common list of (re-)emerging diseases in crisis situation.
Keywords: Epizootic diseases; Emerging diseases; Diagnostic; Laboratories; preparedness; Capacity; 
Prioritisation; Knowledge mapping.
1. INTRODUCTION
An emerging disease can be defined as a disease with an incidence that has been significantly 
increasing compared to its baseline rate, in a determined population and region, and over a determined 
period of time (Toma and Thiry, 2003). A re-emerging disease can be defined as previously contained 
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Most recent pandemics, such as human immunodeficiency virus infection and acquired immune 
deficiency syndrome (HIV/AIDS), severe acute respiratory syndrome, and pandemic influenza, are 
caused by zoonotic pathogens originating from wildlife and for which the emergence was driven by 
ecological, behavioural, or socioeconomic changes (Morse et al., 2012; Bianchini et al., 2020). 
International experts of the World Organisation for Animal Health (OIE), the World Health 
Organization (WHO) and the United Nations for Food and Agriculture Organization (FAO) estimate 
that the risk of (re)-emergence of pathogens has reached an importance and a global impact never 
observed before (King, 2008; Vallat, 2016)  and seems to increase (Anonymous, 2009; Jones et al., 
2008). Indeed, continuing changes in socioeconomic, behavioural, commercial, environmental (e.g. 
deforestation and the decrease/lack of biodiversity, climate change and its consequences like global 
warming and severe rainfalls), political factors and the increase in international travels contribute to 
an amplification of environmental hazards and spread of exotic and (re)-emerging diseases 
(Rodriguez-Prieto et al., 2015; Gebreyes et al., 2014; Souza Monteiro et al., 2012). Additionally, the 
world animal population has been constantly increasing because of a rise in global demand for animal 
products. The majority of this need is located in less developed regions (Gebreyes et al., 2014) and 
are thus considered as hotspots for diseases emergence (Jones et al., 2008). Spatially explicit models 
can be used to identify regions most likely to establish the next emerging zoonoses (so-called hotspots 
of emerging infectious disease) which are located in regions where human activities take place against 
a background of high wildlife biodiversity, with concomitant microbial biodiversity (Morse et al., 
2012). The tropical origin of those diseases could be considered as a threat for the northern 
hemisphere (Reviriego Gordejo et al., 2009) and should be monitored to prevent and rapidly deal with 
outbreaks (Morse et al., 2012). 
Conventional surveillance system for re-emerging diseases is based on passive (clinical) detection 
combined with active sampling. However, conventional passive surveillance on limited number of 
samples is restricted by the diagnostic accuracy, visibility and specificity of clinical signs. Active 
surveillance on random sample surveys is highly expensive and timeless is a limiting factor 
(Rodriguez-Prieto et al., 2015). Therefore, differential diagnosis based on laboratory testing for a 
broad range of diseases is an asset for the identification, control and eradication of the pathogens 
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quality assays are key factors to rapidly diagnose, control and/or eradicate any pathogen (Koenen et 
al., 2007; Muir-Paulik et al., 2016; Vallat, 2016; Westergaard, 2008). However, the OIE pointed out 
that rapid detection of emerging diseases could be improved in developing countries and even in some 
industrialized countries which suffer from deficiency in infrastructure, laboratory capacity and 
veterinary proficiency (Vallat, 2016).
The European legislation harmonized contingency plans for several highly transmissible diseases (e.g. 
European Regulation (EU) 2016/429) but left Member States (MS) free to prioritize and implement 
control strategies. Few scientific articles have focussed on the evaluation of laboratory capabilities to 
tackle (re)emerging diseases (Muir-Paulik et al., 2016) which could leave policy-makers without 
scientifically sound ideas of what they could and should actually strengthen (Savigny and Taghreed, 
2009). Knowledge mapping, a collection of concepts structured hierarchically and populated with 
additional resources that explicates the concepts in a map (Coffey, 2015), could be useful to provide 
an overview of the laboratory capabilities and help for laboratory diagnostic gaps. Two dimensions 
might be considered to define a lack in diagnostic: missing adequate testing procedure at the hand, 
availability and preparedness of diagnostic resources when confronted to an epidemic. 
This study will first review the diagnostic capabilities in Belgium (as an example) for a list of selected 
(re)emerging -26 viral and 3 bacterial- diseases recently published (Bianchini et al., 2020). It will then 
use knowledge mapping to visually identify major and minor gaps(s) in diagnostic in frequent 
epidemiological scenarios. An overview of diagnostic capabilities at international level (laboratories 
and kits providers/manufacturers) as well as the published assays in the scientific literature and the 
prescribed assays by international institutions will help to find collaborations and fill the gaps if 
necessary.
2. MATERIAL AND METHODS
2.1.  List of diseases
For this study, 29 livestock diseases considered as emerging and reemerging disease were used. These 
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Belgium using a multi-criteria decision analysis approach (Bianchini et al., 2020). These diseases 
were African horse sickness, African swine fever, Aino disease, akabane disease, avian influenza, 
bluetongue, Cache Valley virus, classical swine fever virus, contagious bovine pleuropneumonia, 
contagious caprine pleuropneumonia, epizootic haemorrhagic disease, equine encephalomyelitis 
(eastern, western, Venezuelan), foot-and-mouth disease, haemorrhagic septicaemia, Japanese 
encephalitis, lumpy skin disease, Newcastle disease, Nipah virus encephalitis, porcine epidemic 
diarrhoea, porcine deltacoronavirus (novel swine enteric coronavirus disease), Rift Valley fever, peste 
des petits ruminants, Schmallenberg disease, sheep pox and goat pox, swine vesicular disease, 
vesicular stomatitis, West Nile encephalitis. 
2.2.  Inventory of the Belgian diagnostic possibilities and capacities for three 
epidemiological scenarios: input for knowledge mapping 
The need for diagnostic capabilities was assessed according to three classical epidemiological 
scenarios, which are:  the early detection of disease, the characterisation of disease spread and the 
substantiation of freedom of disease as defined by the manual of diagnostic tests and vaccines for 
terrestrial animals from the OIE (http://www.oie.int/en/standard-setting/terrestrial-manual/access-
online/).
A free LimeSurvey® web application survey (Appendix S1) was carried out in 2015 among seven 
major Belgian veterinary laboratories to list the different assays that would be used in these three 
usual epidemiological scenarios. These laboratories were respectively the Federal Veterinary and 
Agrochemical Research Centre (CODA-CERVA), the regional laboratories (Association Régionale de 
Santé et d’Identification Animale (ARSIA) and Dierengezondheidszorg Vlaanderen (DGZ), the 
Public Health Institute (PHI), the Institute of Tropical Medicine of Antwerp and the laboratories of 
the Faculty of Veterinary Medicine of Liège University and Ghent University. Note that he CODA-
CERVA and the Public Health Institute (PHI) were recently grouped in a unique institution, named 
Sciensano. In addition, the crisis emergency diagnosis and crisis management book that includes the 
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Before submission of the questionnaire to the different laboratories, a pilot testing was performed 
with six experts (one responsible of a diagnostic laboratory at CODA-CERVA, a former responsible 
for diagnostic for small ruminants at DGZ, two senior epidemiologists trained in surveys and two 
junior epidemiologists of the CODA-CERVA).
All gathered information was captured in online knowledge maps using Cmap® software version 
6.00.4, available on https://cmap.ihmc.us/. Knowledge maps were used because they have been 
demonstrated to be an effective mean of representing, visualizing, communicating knowledge 
between different stakeholders in the field of public health, improving theory development, acting as a 
sound basis for practical decision-making (Van Bon-Martens et al., 2014). For each disease, three arcs 
link the different scenarios and sub-scenario nodes using a specific colour code. Each node provides 
the tests that would be used in the Belgian laboratories or in the collaborating laboratories if external 
partnerships were in place (Figure 1). 
2.3.  Literature review on diagnostic assays
The aim of this review is to identify the main characteristics of the principal types of assays published 
but above all to guarantee they are used in the correct scenarios in the Belgian laboratories and to help 
finding diagnostic possibilities, if required.
The databases PubMed and Cab Abstract were consulted, considering the inclusion period starting 
from January 2000 and ending in February 2016, to get insight of the different published assays using 
the disease name as search term and using filters (see Appendix S2). The first selected papers are 
those for which the title was explicitly relevant (e.g. including the name of the disease and referring to 
the diagnosis or to a diagnostic test). After reading, within these selected papers, the major selection 
criteria were, in decreasing order of importance, the specific diagnosis of the pathogen (species, 
subspecies if possible) with a current technique, and the mention of the test sensitivity (Se) and/or 
specificity (Sp). A current technique can be defined as a technique still currently recommended in the 
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The different diagnostic methods were subsequently classified according their capacity to detect 
directly or indirectly the pathogen/genome/antigen/antibodies.
2.4.  Identification of diseases with major and minor diagnostic gaps in Belgium
Diseases are included in the group with “major diagnostic gaps” when no diagnostic tool validated for 
animal samples is available for the three scenarios in the Belgian laboratories. Diseases are included 
in the group with “minor diagnostic gaps” when some assays are not available or do not fit for 
purpose for at least one of the three scenarios. Diseases were not considered with diagnostic gaps in 
Belgium if official partnerships were already developed. Partnerships with other European 
laboratories guarantee rapid and reliable suspicion confirmation and support in diagnostic and in 
assays implementation during crisis by European reference laboratories.
Knowledge mapping was used to categorise diseases with major and/or minor diagnostic gaps 
(Figure 2). Then to assess the suitability of the Belgian assays, an expert elicitation was organized 
face-to-face with five team leaders of laboratories at CODA-CERVA. The purpose of this elicitation 
was to give a qualitative appraisal of the assay available regarding to the OIE Manual of Diagnostic 
Tests and Vaccines for Terrestrial Animals as a reference. The qualitative appraisal for each scenario 
was the following: recommended method (+), suitable method (++) or may be used in some situations 
(+++). 
In addition, to judge if the Belgian laboratories have or would have enough capacity to face a crisis, 
the quantity and the type of the different assays performed monthly by the national reference 
laboratory (NRL) and encoded in its Laboratory Information Management System (LIMS) were 
extracted from December 1999 to July 2015, for bluetongue (BT), foot-and-mouth disease (FMD) and 
avian influenza (AI). These diseases require an important capacity per day due to a high possibility to 
rapidly spread and to contaminate a large amount of naïve animals (O'Brien et al., 2017; Agence 
nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail, 2012). During the 
previous crisis CODA-CERVA, as NRL, was the only laboratory allowed to test samples for FMD 
and avian influenza virus (AIV) whereas for bluetongue virus (BTV), next to CODA-CERVA also 
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yearly, from 2006 to 2010 for bluetongue virus (BTV) at ARSIA and DGZ was also computed. These 
data were compared to the already published articles using the following search string performed in 
Cab abstracts “Foot and mouth OR bluetongue OR avian influenza AND laboratory capacit* OR 
epidemics”. 
2.5.  Diseases with major and minor diagnostic gaps in Belgium: inventory of the 
diagnostic possibilities in some European laboratories 
2.5.1. Diagnostic possibilities overview in Europe
To get an overview of the diagnostic possibilities (yes/no) for the 29 selected pathogens across 
Europe, the data available for 40 veterinary European laboratories inventoried in the World Animal 
Health Information System database (WAHIS) 
(https://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Countrylaboratoris) were 
consulted in November 2019 for 23 of the 29 listed diseases. Note that Akabane (AKA), Aino disease 
(AD), Schmallenberg virus (SBV), Cache Valley virus (CVV), Porcine epidemic diarrhoea virus 
(PEDV) and Porcine deltacoronavirus (PDCoV) are currently not included in the OIE list 
(https://www.oie.int/en/animal-health-in-the-world/oie-listed-diseases-2019/).
These data were completed with the diagnosis possibilities in nine western European laboratories 
(NRLs and/or OIE reference centres) close to Belgium  (2 in France, 1 in Germany, 1 in The 
Netherlands, 1 in Italy, 2 in Spain, 1 in Switzerland, 1 in United Kingdom). This information was 
obtained by mail and phone calls.
2.6.  Diseases with minor diagnostic gaps in Belgium: inventory of the diagnostic 
possibility in some European laboratories 
Among these nine laboratories, those with diagnostic possibilities for diseases with minor gaps in 
Belgium were re-contacted to complete the questionnaire for the diseases identified with minor 
diagnostic gaps in Belgium (Figure 2). The OIE Manual of Diagnostic Tests and Vaccines for 
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used for crisis and for surveillance and freedom status establishment scenarios. Only these types of 
assays were considered as a possible solution to fill the gaps in Belgium.
2.7.  Diseases with major diagnostic gaps in Belgium: inventory of the diagnostic 
possibility in some European laboratories 
For the diseases with major gaps in Belgium, the query was extended to 12 OIE laboratories and 5 
major public laboratories and university laboratories located in Western Europe (France: 3, Spain: 2, 
Italy: 1, United Kingdom: 3, The Netherlands: 3, Germany: 2, Denmark: 1, Sweden: 2). They were 
invited to fill the questionnaire for the three scenarios (Figure 2). If no diagnostic possibility exists, 
they were asked if diagnostic would be possible in other laboratories in their own country or in 
Europe (snowball approach).
2.8.  Diseases with major diagnostic gaps in Europe: find diagnostic possibilities in 
laboratories outside Europe 
If less than two assays were available per disease among all these European laboratories, other 
laboratories were contacted via the first author’s address based on the literature review. 
2.9.  
Inventory of the available commercial kits in Europe for the 29 selected diseases 
The CODA-CERVA controls the quality of diagnostic reagents used for official animal disease 
control programs commissioned by the Federal Agency for the Safety of the Food Chain (FASFC). 
Commercial kits manufacturers/providers were selected within those who have controlled batches in 
the CODA-CERVA in 2013-2014. It was followed by a rapid internet search using the following 
algorithm: “disease name” AND “kit” OR “PCR” OR “ELISA” as keywords and Boolean operators. 
All major kits manufacturers/providers were included in the list. They were invited to complete the 
questionnaire (Figure 2). On the other hand, a cross check of the information received from firms was 
performed compared with those implemented on Discontools®. Discontools® is an online database 
with the objective to provide information related to the commercial diagnostic kits availability for 52 
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3. RESULTS
3.1.  Inventory of the Belgian diagnostic possibilities and capacities for three 
epidemiological scenarios: input for knowledge mapping 
The participation rate for the Belgian survey was 100%. Three laboratories were excluded because 
they did not propose routine testing (research only) or did not have diagnostic accreditation for animal 
samples.
A diagnostic possibility exists for 25/29 diseases. For confidential reasons, details concerning fees for 
the commercial kits and for diagnostic performed by European laboratories are not available for the 
public. Data were implemented in knowledge maps and available via this link: 
https://cmapspublic.ihmc.us/rid=1QZQ48NFK-2B2XY0S-
30MB/page%20de%20garde%20EPIDIACAP%20(official).cmap.
3.2.  Identification of diseases with major and minor diagnostic gaps in Belgium 
Four diseases (Nipah virus (NiV), AD, CVV and AKA) are identified as diseases with major 
diagnostic gaps and three diseases (PDCoV, PEDV, haemorrhagic septicaemia (HS)) as diseases with 
minor diagnostic gaps (Table 1).
For PEDV and PDCoV, a validated real-time polymerase chain reaction (qPCR) as well as a 
serological assay for specific identification and discrimination of each pathogen is missing.
For HS samples are subcontracted to a human laboratory using laser desorption ionisation time-of-
flight (Maldi-Tof). An alternative to Maldi-Tof should be implemented in a Belgian veterinary 
laboratory to face massive samples flow and when a serological assay is required. 
Absence of virus isolation (VI) for Rift Valley fever is not considered as a lack because the disease is 
exotic in Europe and a biosafety-level-4 laboratory is required but genome that could be detected by 
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Table 1. Diagnostic possibilities for the 29 (re)-emerging diseases in Belgium (BE) (according to 
Bianchini et al., 2020), in Europe (EU), abroad Europe (INT) and kit availability by major 
manufacturers/providers (MP)
Molecular diagnosis Serological diagnosis
Diseases
BE EU INT MP BE EU INT MP
African horse sickness 0 1 0 0
African swine fever 0 0 0 0
Aino disease 1 1 0 1 1 1 0 1
Akabane 1 0 1 1 0 0
Avian influenza 0 0 0 0
Bluetongue 0 0 0 0
Cache Valley virus 1 1 0 1 1 1 0 1
Classical swine fever virus 0 0 0 0
Contagious bovine pleuropneumonia 0 1 0 0
Contagious caprine pleuropneumonia 0 1 0 0
Epizootic haemorrhagic disease 0 0 0 0
Equine encephalomyelitis (Eastern) 0 1 0 1
Equine encephalomyelitis 
(Venezuelan)
0 1 0 1
Equine encephalomyelitis (Western) 0 0 0 0
Foot and mouth disease 0 0 0 0
Haemorrhagic septicaemia 1* 1 0 1 0 1
Japanese encephalitis 0 1 0 1
Lumpy skin disease 0 0 0 0
Newcastle disease 0 0 0 0
Nipah virus encephalitis 1 1 0 1 1 1 0 1
Porcine epidemic diarrhoea 1 0 0 1 0 0
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Rift Valley Fever 0 1 0 0
Peste des petits ruminants 0 0 0 0
Schmallenberg 0 0 0 0
Sheep pox and goat pox 0 1 0 1
Swine vesicular disease 0 1 0 0
Vesicular stomatitis 0 1 0 1
West Nile encephalitis 0 1 0 1
Total 7 4 0 15 7 4 0 11
Legend: For respectively in Belgium (BE), in Europe (EU), outside Europe (INT) and kit availability 
by major manufacturers/providers (MP), the following code of colour is used: 0, the diagnostic 
possibility exists; 1: diseases with major or minor lack (no diagnostic possibility) and white, no lack 
or possible collaboration already found at BE or EU level. Total indicates the number of diseases for 
which laboratory diagnostic possibilities are still needed. *Samples subcontracted to a human 
laboratory.
Except for BTV, epizootic haemorrhagic disease (EHD) and vesicular stomatitis (VS) for which 
Belgium would use qPCR, results confirm that there is at least one OIE prescribed assay in Belgium, 
for each scenario, taking external partnerships into account. 
Belgium is able to realise several thousand PCR, enzyme-linked immunosorbent assay (ELISA) and 
hemagglutination inhibition (HI) tests (Figures 3 to 5). During this episode, retrospective analysis in 
the LIMS, showed that CODA-CERVA can reach several thousand samples tested per month and 
saturation was not achieved. That means the whole process was efficient enough to enable performing 
the required analysis but also to ensure efficient logistics of the reagents and routing of the samples. 
The highest number of tests by competitive ELISA by the regional laboratories was 18,314 samples 
for ARSIA and 14,711 samples for DGZ in 2007. The mean for these two laboratories together is 
21,578 ELISA tests per year. This flow could be adapted to other diseases. The flow preservation in 
time in crisis depends on the reactive availability and the time of delivery by commercial firms which 
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3.3.  Diseases with major and minor diagnostic gaps in Belgium: inventory of the 
diagnostic possibility in some European laboratories 
3.3.1. Diagnostic possibilities overview in Europe
Data available on WAHIS for 40 European countries showed that 39 countries have diagnostic 
possibilities for Newcastle disease, 37 for AIV, 35 for FMD, CSF and BTV. Only 8 pathogens in the 
list could be diagnosed in more than 20 countries and there is no possibility for NiV (Figure 6). 
In the 8/9 western European laboratories that answered for their diagnostic possibilities for the 29 
diseases, all of them have specific tools for African horse sickness, African and classical swine fever, 
avian influenza, bluetongue, contagious bovine pleuropneumonia, Schmallenberg virus, swine 
vesicular disease, west Nile encephalitis but on the other hand, no possibility was found for CVV 
(Table 2). For AD, only the German laboratory and for NiV, the German (Henipavirus specific) and 
the Italian laboratories, have diagnostic possibilities. Note that based on the literature review, contact 
was also established with a laboratory in Denmark because it recently published an assay for 
haemorrhagic septicaemia that was considered as minor diagnostic lack in Belgium.
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Cache valley virus




Equine encephalomyelitis (Eastern) ST
Equine encephalomyelitis (Western) ST






Peste des petits ruminants
Porcine deltacoronavirus ST S S * R*
Porcine epidemic diarrhoea * R*
Rift Valley Fever
Schmallenberg
Sheep pox and goat pox
Swine vesicular disease
Venezuelan Equine encephalomyelitis ST
Vesicular stomatitis ST
West Nile encephalitis ST
Legend: This table displays the diagnostic possibilities in 8 laboratories located in western European 
countries for the 29 selected diseases (Bianchini et al., 2020) based on mails and phone calls 
enquiries. Note that the two laboratories in Spain gave a common answer. Dark box: diagnostic 
possibility. White box: no diagnostic possibility. ST= subcontract abroad Europe. S=PCR soon 
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3.3.2. Diseases with minor diagnostic gaps in Belgium: inventory of the diagnostic possibilities 
in some European laboratories 
A specific qPCR for PEDV could be implemented from France, Italy and Germany but only the 
Netherlands proposed an optimized ELISA PEDV-specific based on the method published by Van 
Nieuwstadt and Zetstra (1991). Even if PDCoV can be detected with a Pan-coronavirus PCR, as 
implemented in Belgium, there were no specific, validated and commonly used molecular and 
serologic assays in Europe in 2015.
Concerning HS, Italy proposes a biochemical characterization, which is not really specific whereas 
Spain has developed different qPCR for serogrouping and gene virulence. Note that Denmark has 
developed a Multi Locus Sequence Typing (MLST) used in routine and as well as a qPCR (Petersen 
et al., 2014). MLST remains more costly and less throughput than qPCR. No serological assay was 
mentioned for the diagnostic of this bacterium.
3.3.3. Diseases with major diagnostic gaps in Belgium: inventory of the diagnostic possibilities 
in some European laboratories 
Out of the 14/17 of European laboratories which completed the questionnaire, virus isolation, 
molecular and serologic assays were found for AKA in France and Germany. Only one diagnostic 
possibility was found in Europe for AD and CVV. For NiV, a specific PCR and a Henipah virus 
specific serological assays are available. As antibodies to Hendra virus and NiV cross-neutralize to a 
limited degree, ELISAs using Hendra virus or NiV antigen can be adequate to detect antibodies to 
both viruses (World Organisation for Animal Health, 2018b).
3.3.4. Diseases with major diagnostic gaps in Europe: find diagnostic possibilities in 
laboratories outside Europe
Based on the literature, diagnostic capabilities were found in the veterinary institutes in Republic of 
Korea and in Japan for AD (Akashi et al., 1999; Lee et al., 2015; Shin et al., 2009) and in the United-
States for CVV (Wang et al., 2009). Histopathology is also used for the two viruses and is reliable for 
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(VNT), the gold standard serological screening in mammals, which has shown its usefulness in virus 
serogroups, species and subtypes identification (Blitvich et al., 2012; Weir, 2003). Several PCR have 
been developed in different formats (classical, nested, real-time, multiplex) and are used for genome 
detection in animal tissue, blood sample and insects (Lee et al., 2015; Shin et al., 2009; Wang et al., 
2009). 
3.4.  Inventory of the available commercial kits in Europe for the 29 selected diseases 
Considering the results from the eleven major manufacturers/providers (fifteen were contacted), 19 
diseases could be covered with a commercial kit. In proportion, commercial assays available in 
Europe are PCR (30%) and antibodies ELISA (70%) which are not Differentiating Infected from 
Vaccinated Animals (DIVA), excepted for FMD. Three firms propose pen-side tests for African 
swine fever, AIV, BTV and PCRs for less equipped laboratories for AIV, CSF, FMD and Newcastle 
disease. Cross-checking with data available on Discontools®, no kit has been commercially 
developed for AD, CVV, Eastern/western/Venezuelan/Japanese encephalitis, NiV, Sheep and goat 
pox and VS. Caution should be taken when assessing the assay’s sensitivity (Se) and specificity (Sp), 
especially when enssuring perfect sensitivity (Se.) and specificity (Sp). In this case, it should be 
assured that they have not been validated with a too restricted number of animals (<10) that could 
lead to assumed perfect tests (100% Se and 100% Sp) when all test results are positive or negative 
respectively while in reality this can not be the case given the confidence interval ranges for such 
small sample sizes. The first day post infection that the assay can be used is unknown or not evaluated 
for 65% of the kits and the last day is unknown or not evaluated for 74% of the kits.
3.5.  Literature review on diagnostic assays
3.5.1. General assessments
A total of 840 articles were selected. In general, VI and VNT are considered as gold standard 
(MacLachlan and Dubovi, 2011) because of their high Se and Sp. However, because they require 
special equipment, stringent biosecurity measures, long laboratory preparation and a significant time 
before obtaining the results using these methods on a large number of samples in crisis is hampered. 
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number of advantages: higher Sp (due to the probe used), realtime availability of quantitative result 
(due to the measurement of fluorescence), automation (robot for automated deoxyribonucleic acid 
(DNA) extraction), and probability of contamination reduced (closed machine). However, the cost of 
technical equipment is still high especially for small labs or for low-income countries. In addition, a 
variant of these two techniques allows the simultaneous detection of several pathogens (multiplex). 
Advantage is the detection and the identification of virus from the same serogroup (i.e. AKA and AD) 
or virus with potential similar clinical signs (i.e. foetal malformation induced by, BTV, AKA, AD, 
CVV, SBV).
This, however, generally leads to a decrease Se. The major disadvantage of these molecular 
techniques is the inability to determine the viability of the identified agent, the susceptibility to 
contamination and the need to adapt to mutations in the genome. Sequencing uses amplicons of a first 
PCR and allows pathogen identification with great precision. The literature agrees that this technique 
will take an important place in the future for emerging or hard to cultivate pathogens’ identification, 
etiological and phylogenetic research due to the price of the equipment, the need of trained personnel 
and the cost of use, this technique is still only used in well-equipped laboratories for specific 
confirmation and research. Loop mediated isothermal amplification (LAMP), another molecular 
technique, can be applied both in laboratory and in the field and has a high Se and Sp, often 
comparable to the qPCR. Other advantages are the speed at which the results are obtained (20 
minutes) and the low cost per test. However, this technique has yet to be validated for routine use.
Regarding the ELISA for antibodies detection, numerous commercial tests, in-house and variants are 
available and discussed which made the comparison difficult, especially for the Se and the Sp. 
However, their major advantages are speed, ease of use, low cost and the ability to test a large number 
of samples simultaneously. Due to the time required between infection and onset of antibodies, this 
technique is generally applied for serological confirmation (e.g. confirmation of pathogen exposure in 
detection of disease, freedom status). 
Data summarized for the 14 diseases of interest for Belgium present in Discontools® indicates that all 
diseases need improvements (i.e. assay development for Nipah, validation and harmonization, pen 
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3.5.2. Specific assessments for diseases with major and minor diagnostic gaps
Less articles are available and fewer different types of assays have been developed for the diseases 
with major gaps compared to some other (i.e. FMD, BTV). For example, only 9 articles were 
considered as relevant for AD, 5 for CVV, 12 for AKA versus 32 for BTV, 60 for FMD and 134 for 
AIV. However, at least one molecular and serological test was published for each disease.
Differential diagnosis of PEDV and PDCoV (first reported in 2012) is essential to control viral 
diarrhoea but antibody cross-reactivity between porcine enteric coronaviruses remains a major 
concern (Gimenez-Lirola et al., 2017). However, some specific molecular (Ding et al., 2020) and 
serological assays (Kimpston-Burkgren et al., 2020; Lu et al., 2020) allowing specific identification 
were recently published but required to be more largely implemented in all laboratories. 
Some serological tests for HS detection have been published but are not commonly used for 
diagnostic purposes (World Organisation for Animal Health, 2018a), probability due to the few 
number of animals that survive and seroconvert.
3.5.3. Special assessments for vector borne diseases
If it was mentioned that qPCR was a key tool for genome detection, its use inherently depends on the 
presence of the genome in the matrix. Thus, for the viral vector borne diseases part of this study, the 
period of viremia is generally short and appears before the clinical signs, making early diagnosis by 
PCR or VI difficult. In this case, the serological methods are therefore preferred for the diagnostic. It 
also appears that serological confirmation of Flavivirus encephalitis remains difficult, in particular 
because of cross-reactions and absence of field test.
4. DISCUSSION
Diagnostic assays are routinely used in laboratories to demonstrate the presence or absence of current 
and/or past infections in different settings (i.e. early detection, characterisation of spread and freedom 
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in wild and domestic animals, an effective laboratory service should be a priority before they become 
a threat to the public health and the animal health sectors. Europe already imposes to the member 
states to be efficient to face a crisis for some few listed animal diseases (European Regulation (EU) 
2016/429) but it seems relevant to also be ready to face all potential emerging threats in different 
epidemiological scenarios. The actual epidemiologic situation seems under control for usual diseases, 
leading us to focus on the current diseases or the crisis of the moment rather than prioritizing our 
investments for emerging diseases. Due to this absence of urgent need and common guidelines at the 
European level, countries have adopted several strategies to prepare themselves to emerging diseases 
differently. Consequently, they have implemented different assays they consider to be the most 
suitable.
Countries should collaborate to develop a common list of diseases in the framework of a one health 
approach (wild life, animal health, human health) and each country should evaluate its own diagnostic 
capability to be sure to be efficient if the diseases appear. However, there is no published method 
applicable at the country level to overview the capabilities and over which tests should be 
implemented. Knowledge maps have been widely used and have proved to be valuable tools for 
description, classification and generalization of data (Ho et al., 2018) but to the authors’ knowledge, it 
is the first time they are shown to be useful to provide an overview of the laboratory possibilities and 
capacities.
Several parameters should be considered to evaluate the capabilities: the type of gaps (major or 
minor) at national level, the possibility to find collaborations abroad, the kits availability from 
commercial firms, the diagnostic capacity, in the light of the scientific literature. 
If diagnostic gaps are identified, without common and mandatory guidelines for all European 
laboratories, the OIE prescribed assays are considered as the reference. However, it is important to 
cross information from different scientific sources (e.g. the scientific literature, the OIE 
recommendations and Discontools®) to identify ‘fake’ gaps. As example, for African horse sickness, 
it is not relevant to detect the pathogen in blood during a crisis because of really short viremia 
duration. Not having any molecular assay in place cannot be considered as a gap. On the other side, 
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scientific published articles. As example, there is a considerable variation in the diagnostic approach 
of BTV and EHD (Wilson et al., 2015). OIE does not promote PCR for BTV and EHD eradication 
and prescribes serology, probably because it has been intensively used and validated for surveillance 
and evaluation of mass vaccination (Katz et al., 2011). However, serology reveals the presence of 
antibodies either following past pathogen infection or transfer of maternal immunity and not 
necessarily active infection. On the other side, major limitations of PCR for these viruses are the 
possible detection of nucleic acids several weeks after the infection in animals no longer infectious as 
well as its susceptibility to contamination and its cost. In case of doubt, only VI could demonstrate the 
presence of the viable virus. In addition, laboratories must be able to adapt to the genetic diversity of 
the two viruses by selecting the most suitable probes for the new isolates. The experience acquired 
during the BTV-8 crisis in Belgium has shown the interest and complementarity of PCR and ELISA 
in different epidemiological scenarios (Vandenbussche et al., 2018; Welby et al., 2013). Even if 
genome could be detected earlier than antibodies in blood, PCR use costs 3 to 9 times more per 
sample than the ELISA and could explain why the last method is privileged when possible. Vesicular 
stomatitis is another example: the recommendation for eradication is to use serological tests (ELISA, 
VNT), which detect antibodies 5-8 days after infection. The competitive ELISA assay has become the 
serological test of choice for screening purposes in the United States during outbreaks of VS 
(European Food Safety Authority, 2012). A positive result indicates only previous exposure and 
requires, when interpreting the results, to also rely on the presence of clinical signs and to take into 
account the epidemiological situation. PCR can be performed 1-2 days before the appearance of 
lesions but is not particularly recommended by OIE because it cannot determine if the virus is 
infectious and because that tool is not routinely used for screening diagnostic cases for virus causing 
VS (World Organisation for Animal Health, 2015).  
To find diagnostic possibilities, online knowledge maps could be used as a common modern media for 
communication and sharing information between laboratories. The One Health approach encourages 
collaborations between countries but the different medical disciplines and sectors have already 
developed their own country-specific diagnostic network with different levels of laboratories (i.e. 
WHO/OIE reference laboratories, NLR, regional laboratories, private laboratories). This stratification 
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flows online could permit to rapidly identify and connect the national, regional and international 
laboratories and entities to provide technical support and to establish or strengthening multilateral 
cooperation within a One Health laboratory network. They could also help to easier identify gaps in 
diagnostic as an alternative to Discontools ®, to enhance collaborations at international level, to share 
diagnostic experience and to harmonize diagnostic procedure based on the most recent scientific 
publication. However, maps need to be regularly updated to avoid contradiction, as it was observed 
when comparing data implemented in WAHIS (release date in 2013 but does not seem updated since) 
and the data gathered directly by contacting the laboratories. As example of possible collaboration, 
this article underlined disparities in sensitivity and specificity and in the window post-
infection/inoculation during which the assays can be used. Explanation could be found, independently 
of the assay, due to the lack of investment to completely evaluate rare disease, the different study 
protocols in the different countries, including a variable number of animals, species, breeds, ages, 
inoculation method, strain and dose injected. Test interpretation, especially the determined cut-off, is 
subject to modifications. In vivo evaluations and meta-analysis would be useful to fill these gaps, 
which could be achieved in a cheaper way within a European consortium. 
It is also impractical and excessively costly for most countries to maintain a national veterinary 
diagnostic laboratory that has full capabilities for confirmatory diagnosis of all emergency diseases. 
Another example of collaboration could be to enhance materials and samples dedicated for the 
different epidemiological scenarios, enhance different cooperation between countries to reduce the 
cost of diagnostic kits development, validation and renewal. To guarantee sufficient resources in 
times of reduced financial attribution, a European kit stock could be elaborated with design reference 
laboratories in charge to accredit assays, to ensure a rapid help if requested, to better cover the 
emerging diseases and to supply sufficient harmonization of international guidelines and standards for 
laboratories.
It is challenging to evaluate the required diagnostic capacity because this information is rarely 
published and countries do not make it public. This could be evaluated by combining crisis spread 
modelling, literature review (published data based on previous crisis), and by experts elicitation. For 
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number of samples submitted. For FMD, based on Bouma (2003) (Bouma et al., 2003), Belgium 
seems to have enough capacity to face a crisis. This article clearly mentions the capacity developed 
during the FMD crisis in the Netherlands in 2001. During the month the crisis occurred, 78 samples 
(standard deviation 61) samples were daily analysed by antigen ELISA and, when vaccination began, 
50 000  samples weekly by DIVA serology. Belgium could develop much more diagnostic capacities 
even if animal density is lower compared to the Dutch region where FMD outbreak happened. 
For the other diseases still exotic to Belgium but for which diagnostic possibilities are available, the 
NRL prepared itself to face an emergence. To do so, a crisis manual was elaborated in which for each 
disease and for each test available important information is listed such as the maximum daily 
capacities per person and in total, the collaborations with other laboratories in Belgium and abroad, 
the time required before results will be available. This manual is regularly updated and validated by 
experts working for the FASFC.
To make comparisons between countries possible, it is more relevant to base assessments on daily 
diagnostic capacity needed by animal density than on only on a diagnostic capacity achievable per 
day.  
This study highlighted the potential usefulness of knowledge mapping in identifying diagnostic gaps. 
However, it was limited to Belgium and did not include a real systematic review of literature. A 
proposal for future research would be to have the tool shared on the web in order to involve other 
countries and to combine it with systematic review.
In conclusion, this study underlined the necessity for each European country to evaluate its diagnostic 
capabilities for a common list of (re-)emerging diseases in order to be prepared. Knowledge mapping 
could be a useful tool not only to visually identify major and minor lack(s) in diagnostic in frequent 
epidemiological scenarios but also for sharing knowledge and enhance collaborations with other 
countries.
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Figure and appendix captions
Figure 1. Knowledge mapping structure used to highlight diagnostic gaps in three epidemiological 
scenarios (early detection, disease spread, and freedom)
Figure 2. Decision tree to categorise diseases with major and minor diagnostic gaps in Belgium
Legend: LIMS, laboratory information management system; AIV, avian influenza virus; FMD, foot-
and-mouth disease; BTV, Bluetongue virus; OIE, World Organisation for Animal Health.
Figure 3. Number of tests for foot and mouth disease per month realized at the CODA-CERVA from 
December 1999 to December 2001 
Figure 4. Number of tests for bluetongue disease per month realized at the CODA-CERVA from 
April 2006 to April 2015
Figure 5a. Number of test for avian influenza tests per month realized at the CODA-CERVA from 
January 2000 and March 2015 
Figure 5b. Number of avian influenza PCR monthly realized at the CODA-CERVA from January 
2003 and July 2015 
 
Figure 6. Number of European countries with diagnostic possibility per pathogen, based on the World 
Animal Health Information System (WAHIS) database
Legend: WAHIS, World Animal Health Information System. European countries encoded in the 
WAHIS database also includes non-European union member states.
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Appendix S2. Filters used for the literature review in PubMed and Cab Abstract
Appendix S3. Identification of diagnostic requirements for 14 diseases of interest for Belgium present 
in Discontools®
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